After treatment of nifekalant, 23 of 27 patients showed termination of VF/VT, as compared with 15 of 28 patients treated with lidocaine (P=0.03) with/without additional shock.

Results date posted

Results Delayed

Results Delay Reason

Date of the first journal publication of results

Baseline Characteristics

Participant flow

Adverse events

Outcome measures

Plan to share IPD

IPD sharing Plan description

Progress

Recruitment status

Completed

Date of protocol fixation

2005

Year

06

Month

25

Day

Date of IRB

Anticipated trial start date

2005

Year

07

Month

01

Day

Last follow-up date

2008

Year

03

Month

01

Day

Date of closure to data entry

2008

Year

10

Month

01

Day

Date trial data considered complete

2008

Year

10

Month

01

Day

Date analysis concluded

2009

Year

02

Month

01

Day

Other

Other related information

In total, 55 patients were enrolled. After treatment of nifekalant, 22 of 27 patients showed termination of VF/VT, as compared with 15 of 28 patients treated with lidocaine (P=0.03) with/without additional shock. 23 of 27 patients with nifekalant showed return of spontanous circulation, as compared with 15 of 28 patients with lidocaine (P=0.01). There was a higher incidence of asystole and pulseless electrical activity with lidocaine (7 of 28 patients) than with nifekalant (0 of 27 patients) (P=0.005).